We are live on
!
Find out more
ACA
Avoro Capital Advisors Portfolio holdings
AUM
$10.2B
1-Year Est. Return
149.19%
This Fund
S&P 500
This Quarter
Est. Return
+24.53%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$2.89B
AUM Growth
+$580M
(+25%)
Cap. Flow
+$390M
Cap. Flow
% of AUM
13.47%
Top 10 Holdings %
Top 10 Hldgs %
71.19%
Holding
39
New
7
Increased
11
Reduced
4
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioMarin Pharmaceuticals
BMRN
|
+$85.1M |
| 2 |
ATNX
Athenex, Inc. Common Stock
ATNX
|
+$63.8M |
| 3 |
IMMU
Immunomedics Inc
IMMU
|
+$49.4M |
| 4 |
ADVM
Adverum Biotechnologies
ADVM
|
+$29M |
| 5 |
PTC Therapeutics
PTCT
|
+$27M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MDCO
Medicines Co
MDCO
|
+$20.8M |
| 2 |
Assembly Biosciences
ASMB
|
+$17.7M |
| 3 |
Establishment Labs
ESTA
|
+$11.4M |
| 4 |
Indaptus Therapeutics
INDP
|
+$9.46M |
| 5 |
AMRN
Amarin Corp
AMRN
|
+$9.16M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 88.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Pacira BioSciences
PCRX
$1.04B
| $17.4M | 0.6% |
400,000
| – | – |
|
27
Adaptive Biotechnologies
ADPT
$3.59B
| $9.66M | 0.33% |
+200,000
| New | +$8.86M |
|
28
Kodiak Sciences
KOD
$2.6B
| $6.75M | 0.23% |
577,021
-50,000
| -8% | -$445K |
|
|
ALIM
29
DELISTED
Alimera Sciences
ALIM
| $5.55M | 0.19% |
416,000
| – | – |
|
30
CALL
Sarepta Therapeutics
SRPT
$1.57B
| $5.46M | 0.19% |
+250,000
| New | +$30.4M |
|
31
Fennec Pharmaceuticals
FENC
$332M
| $4.42M | 0.15% |
1,105,999
| – | – |
|
32
Rocket Pharmaceuticals
RCKT
$340M
| $4.29M | 0.15% |
+285,714
| New | +$4.99M |
|
|
33
Indaptus Therapeutics
INDP
$172M
| $3.56M | 0.12% |
366
-750
| -67% | -$9.46M |
|
|
TLGT
34
DELISTED
Teligent, Inc
TLGT
| $3.3M | 0.11% |
523,121
| – | – |
|
35
PUT
iShares Russell 2000 ETF
IWM
$79.8B
| $110K | ﹤0.01% |
+250,000
| New | +$38.5M |
|
|
36
Assembly Biosciences
ASMB
$498M
| – | – |
-75,000
| Closed | -$17.7M |
|
|
37
Establishment Labs
ESTA
$2.72B
| – | – |
-475,000
| Closed | -$11.4M |
|
38
Outlook Therapeutics
OTLK
$183M
| – | – |
-4,250
| Closed | -$630K |
|
39
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.95B
| – | – |
-1,000,000
| Closed | -$1.27M |
|
Similar funds
IIM
GI
VPIM
RA
OIA
RI
HRCM
WAM
Avoro Capital Advisors's Q2 2019 Portfolio in Review
As of Q2 2019, Avoro Capital Advisors held 39 positions worth $2.89B, up 25% from $2.31B the previous quarter. Its ten largest holdings account for 71% of the portfolio.
Avoro Capital Advisors deployed $390M of net new capital in Q2 2019, opening 7 new positions and adding to 11 existing holdings. Its largest new stake was Athenex, Inc. Common Stock: 230,250 shares worth $91.2M.
By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 83% a quarter earlier.
On the sell side, the largest reduction was Medicines Co, an estimated $20.8M trimmed.
- Avoro Capital Advisors's largest Q2 2019 buy was Athenex, Inc. Common Stock: 230,250 shares worth $91.2M.
- Avoro Capital Advisors added most to BioMarin Pharmaceuticals in Q2 2019, an estimated $85.1M increase.
- Avoro Capital Advisors's biggest Q2 2019 reduction was Medicines Co, cutting an estimated $20.8M.
- Avoro Capital Advisors fully exited Assembly Biosciences in Q2 2019, selling an estimated $17.7M.
- Avoro Capital Advisors's ten largest holdings make up 71% of its $2.89B portfolio in Q2 2019.
- Avoro Capital Advisors opened 7 new positions and closed 4 in Q2 2019.
- Avoro Capital Advisors's portfolio value rose 25% quarter-over-quarter to $2.89B.
Based on Avoro Capital Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.